LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
Year: 2015
Type: conference-abstract
Source: Annals of Oncology
Institutions: Universitair Ziekenhuis Leuven, University of California, San Francisco, Hôpital Saint-Antoine, Sarah Cannon, The Netherlands Cancer Institute, Pinnacle Oncology Hematology, University of North Carolina at Chapel Hill, National Cancer Center Hospital East, Aichi Cancer Center, University of Pennsylvania, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Birmingham, Institut Gustave Roussy, Amgen (United States), Novartis (United States), Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1867801010